Global Market Report

Global Urological Cancer Drugs Market Professional Research Report 2013-2025, Segmented by Players, Types, End-Users in Major 40 Countries or Regions

  • POSTDATE：Nov 15, 2018
  • PAGES：161
  • REPORT CODE：GMM126715
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Driven by the downstream end-users, the market of Urological Cancer Drugs witnessed a growth from XX.00 Million USD in 2013 to XX.00 Million USD in 2018, with a CAGR of XX.00%. Moreover, the forecast of 2018-2025 Urological Cancer Drugs market is offered. The research provides insights for the global Urological Cancer Drugs market based on different Types, End-Users and Regions, and competitive landscape of these segments are analyzed in detail.


    A wide range of market influence factors are taken into consideration in the analysis, and potential developing factors for different Types, End-Users and Regions are also included in the report in order to figure out the most promising development trends in the Urological Cancer Drugs industry. For presenting the most potential investment fields in North America, Europe, Asia Pacific and Latin America, Middle East & Africa, the market capacity and consumption potential of more than 34 major powers are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.


    The Snapshot of Global Urological Cancer Drugs Market Segmentations:

    By Players:

    • Abbott Laboratories

    • GlaxoSmithKline

    • Roche Healthcare

    • Bristol-Myers Squibb

    • Ipsen

    • Celgene Corporation

    • Astellas

    • Johnson & Johnson

    • Dendreon Corporation

    • Tolmar Inc

    • Pfizer

    • Indevus Pharmaceuticals Inc

    • AstraZeneca

    • Sanofi S.A.

    • Novartis

    • Ferring Pharmaceuticals


    By Types:

    • Xofigo (Radium Ra 223 Dichloride)

    • Jevtana (Cabazitaxel)

    • Inlyta (Axitinib)

    • Votrient (Pazopanib Hydrochloride)

    • Sutent (Sunitinib Malate)

    • Zytiga (Abiraterone Acetate)

    • Xtandi (Enzalutamide)

    • Opdivo (Nivolumab)

    • Provenge (Sipuleucel-T)


    By End-User:

    • Prostate Cancer

    • Bladder Cancer

    • Kidney Cancer

    • Testicular Cancer


    By Regions:

    North America

    • United States

    • Canada

    • Mexico


    Europe

    • Germany

    • UK

    • France

    • Italy

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

    • Spain

    • Belgium

    • Poland

    • Russia

    • Turkey

    • Others


    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia and New Zealand

    • ASEAN Countries (Indonesia, Thailand, Malaysia, Singapore, Philippines, Vietnam, Others)


    Latin America, Middle East & Africa

    • GCC Countries (Saudi Arabia, United Arab Emirates, Qatar, Others)

    • Brazil

    • Nigeria

    • South Africa

    • Argentina

    • Others


    Reasons to Purchase the Urological Cancer Drugs Market Report

    • Vertical Market Divisions by Type and End-Users

    • The Most Promising Regions in the Forecast Period

    • Competitive Landscape

    • Key Players’ Strategies and Their Product Offerings

    • Urological Cancer Drugs Market Current Trends/Restraints/Challenges/Opportunities

    • Potential and Niche Market / Regions with Promising Growth

    • Objective Analysis Towards Market Performance

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Urological Cancer Drugs Market

    • 1.3 Market Segmentation by Type

      • 1.3.1 Global Urological Cancer Drugs Market Share by Types

      • 1.3.2 Global Urological Cancer Drugs Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride) from 2013 to 2025

      • 1.3.3 Global Urological Cancer Drugs Market Size and Growth Rate of Jevtana (Cabazitaxel) from 2013 to 2025

      • 1.3.4 Global Urological Cancer Drugs Market Size and Growth Rate of Inlyta (Axitinib) from 2013 to 2025

      • 1.3.5 Global Urological Cancer Drugs Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride) from 2013 to 2025

      • 1.3.6 Global Urological Cancer Drugs Market Size and Growth Rate of Sutent (Sunitinib Malate) from 2013 to 2025

      • 1.3.7 Global Urological Cancer Drugs Market Size and Growth Rate of Zytiga (Abiraterone Acetate) from 2013 to 2025

      • 1.3.8 Global Urological Cancer Drugs Market Size and Growth Rate of Xtandi (Enzalutamide) from 2013 to 2025

      • 1.3.9 Global Urological Cancer Drugs Market Size and Growth Rate of Opdivo (Nivolumab) from 2013 to 2025

      • 1.3.10 Global Urological Cancer Drugs Market Size and Growth Rate of Provenge (Sipuleucel-T) from 2013 to 2025

    • 1.4 Market Segmentation by End-Users

      • 1.4.1 Global Urological Cancer Drugs Market Share by End-Users

      • 1.4.2 Global Urological Cancer Drugs Market Size and Growth Rate of Prostate Cancer from 2013 to 2025

      • 1.4.3 Global Urological Cancer Drugs Market Size and Growth Rate of Bladder Cancer from 2013 to 2025

      • 1.4.4 Global Urological Cancer Drugs Market Size and Growth Rate of Kidney Cancer from 2013 to 2025

      • 1.4.5 Global Urological Cancer Drugs Market Size and Growth Rate of Testicular Cancer from 2013 to 2025

    • 1.5 Market Segmentation by Regions

      • 1.5.1 North America Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.1.1 United States Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.1.2 Canada Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.1.3 Mexico Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

      • 1.5.2 Europe Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.1 Germany Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.2 UK Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.3 France Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.4 Italy Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.5 Nordic Countries Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.6 Spain Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.7 BelgiumUrological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.8 Poland Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.9 Russia Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.2.10 Turkey Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

      • 1.5.3 Asia-Pacific Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.3.1 China Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.3.2 Japan Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.3.3 Australia and New Zealand Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.3.4 India Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.3.5 ASEAN Countries Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.3.6 South Korea Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

      • 1.5.4 Latin America, Middle East & Africa Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.4.1 GCC Countries Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.4.2 Brazil Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.4.3 Nigeria Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.4.4 South Africa Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

        • 1.5.4.5 Argentina Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025


    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints 

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants


    3 Segmentation of Urological Cancer Drugs Market by Types

    • 3.1 Product Development Trends of Different Types

    • 3.2 Commercial Product Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Urological Cancer Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride)

      • 3.4.2 Market Size and Growth Rate of Jevtana (Cabazitaxel)

      • 3.4.3 Market Size and Growth Rate of Inlyta (Axitinib)

      • 3.4.4 Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride)

      • 3.4.5 Market Size and Growth Rate of Sutent (Sunitinib Malate)

      • 3.4.6 Market Size and Growth Rate of Zytiga (Abiraterone Acetate)

      • 3.4.7 Market Size and Growth Rate of Xtandi (Enzalutamide)

      • 3.4.8 Market Size and Growth Rate of Opdivo (Nivolumab)

      • 3.4.9 Market Size and Growth Rate of Provenge (Sipuleucel-T)


    4 Segmentation of Urological Cancer Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Urological Cancer Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Urological Cancer Drugs for Prostate Cancer

      • 4.4.2 Market Size and Growth Rate of Urological Cancer Drugs for Bladder Cancer

      • 4.4.3 Market Size and Growth Rate of Urological Cancer Drugs for Kidney Cancer

      • 4.4.4 Market Size and Growth Rate of Urological Cancer Drugs for Testicular Cancer


    5 Market Analysis by Major Regions

    • 5.1 Global Urological Cancer Drugs Production Analysis by Major Regions

    • 5.2 Global Urological Cancer Drugs Consumption Analysis by Major Regions

    • 5.3 Global Urological Cancer Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 North America Urological Cancer Drugs Production, Import, Consumption and Export Analysis 

      • 5.3.2 Europe Urological Cancer Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 Asia Pacific Urological Cancer Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Latin America, Middle East & Africa Urological Cancer Drugs Production, Import, Consumption and Export Analysis


    6 Product Commodity of Urological Cancer Drugs Market in Major Countries

    • 6.1 Top 5 Export Countries in Urological Cancer Drugs market from 2013 to 2018

      • 6.1.1 Top 5 Export Countries' Export Value Analysis in Urological Cancer Drugs market from 2013 to 2018

      • 6.1.2 Top 5 Export Countries'  Export Volume Analysis in Urological Cancer Drugs market from 2013 to 2018

    • 6.2 Top 5 Import Countries in Urological Cancer Drugs market from 2013 to 2018

      • 6.2.1 Top 5 Import Countries' Import Value Analysis in Urological Cancer Drugs market from 2013 to 2018

      • 6.2.2 Top 5 Import Countries' Import Volume Analysis in Urological Cancer Drugs market from 2013 to 2018

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis


    7 North America Urological Cancer Drugs Landscape Analysis

    • 7.1 North America Urological Cancer Drugs Landscape Analysis by Major Types

    • 7.2 North America Urological Cancer Drugs Landscape Analysis by Major End-Users

    • 7.3 North America Urological Cancer Drugs Landscape Analysis by Major Countries

      • 7.3.1 United States Urological Cancer Drugs Market Volume and Growth Rate

      • 7.3.2 Canada Urological Cancer Drugs Market Volume and Growth Rate

      • 7.3.3 Mexico Urological Cancer Drugs Market Volume and Growth Rate


    8 Europe Urological Cancer Drugs Landscape Analysis

    • 8.1 Europe Urological Cancer Drugs Landscape Analysis by Major Types

    • 8.2 Europe Urological Cancer Drugs Landscape Analysis by Major End-Users

    • 8.3 Europe Urological Cancer Drugs Landscape Analysis by Major Countries

      • 8.3.1 Germany Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.2 UK Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.3 France Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.4 Italy Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.5 Nordic Countries Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.6 Spain Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.7 Belgium Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.8 Poland Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.9 Russia Urological Cancer Drugs Market Volume and Growth Rate

      • 8.3.10 Turkey Urological Cancer Drugs Market Volume and Growth Rate


    9 Asia Pacific Urological Cancer Drugs Landscape Analysis

    • 9.1 Asia Pacific Urological Cancer Drugs Landscape Analysis by Major Types

    • 9.2 Asia Pacific Urological Cancer Drugs Landscape Analysis by Major End-Users

    • 9.3 Asia Pacific Urological Cancer Drugs Landscape Analysis by Major Countries

      • 9.3.1 China Urological Cancer Drugs Market Volume and Growth Rate

      • 9.3.2 Japan Urological Cancer Drugs Market Volume and Growth Rate

      • 9.3.3 Australia and New Zealand Urological Cancer Drugs Market Volume and Growth Rate

      • 9.3.4 India Urological Cancer Drugs Market Volume and Growth Rate

      • 9.3.5 ASEAN Countries Urological Cancer Drugs Market Volume and Growth Rate

      • 9.3.6 South Korea Urological Cancer Drugs Market Volume and Growth Rate


    10 Latin America, Middle East & Africa Urological Cancer Drugs Landscape Analysis

    • 10.1 Latin America, Middle East & Africa Urological Cancer Drugs Landscape Analysis by Major Types

    • 10.2 Latin America, Middle East & Africa Urological Cancer Drugs Landscape Analysis by Major End-Users

    • 10.3 Latin America, Middle East & Africa Urological Cancer Drugs Landscape Analysis by Major Countries

      • 10.3.1 GCC Countries Urological Cancer Drugs Market Volume and Growth Rate

      • 10.3.2 Brazil Urological Cancer Drugs Market Volume and Growth Rate

      • 10.3.3 Nigeria Urological Cancer Drugs Market Volume and Growth Rate

      • 10.3.4 South Africa Urological Cancer Drugs Market Volume and Growth Rate 

      • 10.3.5 Argentina Urological Cancer Drugs Market Volume and Growth Rate

       

    11 Major Players Profile

    • 11.1 Abbott Laboratories

      • 11.1.1 Abbott Laboratories Company Profile and Development Status

      • 11.1.2 Market Performance

      • 11.1.3 Product and Service Introduction

    • 11.2 GlaxoSmithKline

      • 11.2.1 GlaxoSmithKline Company Profile and Development Status

      • 11.2.2 Market Performance

      • 11.2.3 Product and Service Introduction

    • 11.3 Roche Healthcare

      • 11.3.1 Roche Healthcare Company Profile and Development Status

      • 11.3.2 Market Performance

      • 11.3.3 Product and Service Introduction

    • 11.4 Bristol-Myers Squibb

      • 11.4.1 Bristol-Myers Squibb Company Profile and Development Status

      • 11.4.2 Market Performance

      • 11.4.3 Product and Service Introduction

    • 11.5 Ipsen

      • 11.5.1 Ipsen Company Profile and Development Status

      • 11.5.2 Market Performance

      • 11.5.3 Product and Service Introduction

    • 11.6 Celgene Corporation

      • 11.6.1 Celgene Corporation Company Profile and Development Status

      • 11.6.2 Market Performance

      • 11.6.3 Product and Service Introduction

    • 11.7 Astellas

      • 11.7.1 Astellas Company Profile and Development Status

      • 11.7.2 Market Performance

      • 11.7.3 Product and Service Introduction

    • 11.8 Johnson & Johnson

      • 11.8.1 Johnson & Johnson Company Profile and Development Status

      • 11.8.2 Market Performance

      • 11.8.3 Product and Service Introduction

    • 11.9 Dendreon Corporation

      • 11.9.1 Dendreon Corporation Company Profile and Development Status

      • 11.9.2 Market Performance

      • 11.9.3 Product and Service Introduction

    • 11.10 Tolmar Inc

      • 11.10.1 Tolmar Inc Company Profile and Development Status

      • 11.10.2 Market Performance

      • 11.10.3 Product and Service Introduction

    • 11.11 Pfizer

      • 11.11.1 Pfizer Company Profile and Development Status

      • 11.11.2 Market Performance

      • 11.11.3 Product and Service Introduction

    • 11.12 Indevus Pharmaceuticals Inc

      • 11.12.1 Indevus Pharmaceuticals Inc Company Profile and Development Status

      • 11.12.2 Market Performance

      • 11.12.3 Product and Service Introduction

    • 11.13 AstraZeneca

      • 11.13.1 AstraZeneca Company Profile and Development Status

      • 11.13.2 Market Performance

      • 11.13.3 Product and Service Introduction

    • 11.14 Sanofi S.A.

      • 11.14.1 Sanofi S.A. Company Profile and Development Status

      • 11.14.2 Market Performance

      • 11.14.3 Product and Service Introduction

    • 11.15 Novartis

      • 11.15.1 Novartis Company Profile and Development Status

      • 11.15.2 Market Performance

      • 11.15.3 Product and Service Introduction

    • 11.16 Ferring Pharmaceuticals

      • 11.16.1 Ferring Pharmaceuticals Company Profile and Development Status

      • 11.16.2 Market Performance

      • 11.16.3 Product and Service Introduction


    12 Data Source and Research Methodology


    The List of Tables and Figures (Totals 82 Figures and 137 Tables)

    • Figure Product Picture

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Jevtana (Cabazitaxel) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Inlyta (Axitinib) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Sutent (Sunitinib Malate) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Zytiga (Abiraterone Acetate) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Xtandi (Enzalutamide) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Opdivo (Nivolumab) from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Provenge (Sipuleucel-T) from 2013 to 2025

    • Figure Market Share by Type in 2013

    • Figure Market Share by Type in 2017

    • Figure Market Share by Type in 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Prostate Cancer from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Bladder Cancer from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Kidney Cancer from 2013 to 2025

    • Figure Global Urological Cancer Drugs Market Size and Growth Rate of Testicular Cancer from 2013 to 2025

    • Figure Market Share by End-User in 2013

    • Figure Market Share by End-User in 2017

    • Figure Market Share by End-User in 2025

    • Figure North America Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure United States Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Canada Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Mexico Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Europe Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Germany Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure UK Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure France Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Italy Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Nordic Countries Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Spain Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Belgium Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Poland Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Russia Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Turkey Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Asia-Pacific Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure China Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Japan Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Australia and New Zealand Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure India Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure ASEAN Countries Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure South Korea Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure GCC Countries Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Brazil Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Nigeria Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure South Africa Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Argentina Urological Cancer Drugs Consumption Market Size and Growth Rate from 2013 to 2025

    • Figure Development Trends and Industry Dynamics of Urological Cancer Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2017

    • Figure Market Share of TOP 5 Players in 2017

    • Figure Market Share of TOP 6 Players from 2013 to 2018

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Urological Cancer Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Urological Cancer Drugs by Different Types from 2013 to 2025

    • Table Consumption Share of Urological Cancer Drugs by Different Types from 2013 to 2025

    • Figure Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride)

    • Figure Market Size and Growth Rate of Jevtana (Cabazitaxel)

    • Figure Market Size and Growth Rate of Inlyta (Axitinib)

    • Figure Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride)

    • Figure Market Size and Growth Rate of Sutent (Sunitinib Malate)

    • Figure Market Size and Growth Rate of Zytiga (Abiraterone Acetate)

    • Figure Market Size and Growth Rate of Xtandi (Enzalutamide)

    • Figure Market Size and Growth Rate of Opdivo (Nivolumab)

    • Figure Market Size and Growth Rate of Provenge (Sipuleucel-T)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Urological Cancer Drugs by Different End-Users from 2013 to 2025

    • Table Consumption Share of Urological Cancer Drugs by Different End-Users from 2013 to 2025

    • Figure Market Size and Growth Rate of Prostate Cancer

    • Figure Market Size and Growth Rate of Bladder Cancer

    • Figure Market Size and Growth Rate of Kidney Cancer

    • Figure Market Size and Growth Rate of Testicular Cancer

    • Table Global Urological Cancer Drugs Production by Major Regions

    • Table Global Urological Cancer Drugs Production Share by Major Regions

    • Figure Global Urological Cancer Drugs Production Share by Major Regions in 2013

    • Figure Global Urological Cancer Drugs Production Share by Major Regions in 2018

    • Figure Global Urological Cancer Drugs Production Share by Major Regions in 2025

    • Table Global Urological Cancer Drugs Consumption by Major Regions

    • Table Global Urological Cancer Drugs Consumption Share by Major Regions

    • Figure Global Urological Cancer Drugs Consumption Share by Major Regions in 2013

    • Figure Global Urological Cancer Drugs Consumption Share by Major Regions in 2018

    • Figure Global Urological Cancer Drugs Consumption Share by Major Regions in 2025

    • Table North America Urological Cancer Drugs Production, Import, Consumption and Export Analysis

    • Table Europe Urological Cancer Drugs Production, Import, Consumption and Export Analysis

    • Table Asia Pacific Urological Cancer Drugs Production, Import, Consumption and Export Analysis

    • Table Latin America, Middle East & Africa Urological Cancer Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Urological Cancer Drugs market from 2013 to 2018

    • Table Top 5 Export Countries' Export Volume Analysis in Urological Cancer Drugs market from 2013 to 2018

    • Table Top 5 Import Countries' Import Value Analysis in Urological Cancer Drugs market from 2013 to 2018

    • Table Top 5 Import Countries' Import Volume Analysis in Urological Cancer Drugs market from 2013 to 2018

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table North America Urological Cancer Drugs Consumption by Types from 2013 to 2025

    • Table North America Urological Cancer Drugs Consumption Share by Types from 2013 to 2025

    • Figure North America Urological Cancer Drugs Consumption Share by Types in 2013

    • Figure North America Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure North America Urological Cancer Drugs Consumption Share by Types in 2025

    • Table North America Urological Cancer Drugs Consumption by End-Users from 2013 to 2025

    • Table North America Urological Cancer Drugs Consumption Share by End-Users from 2013 to 2025

    • Figure North America Urological Cancer Drugs Consumption Share by End-Users in 2013

    • Figure North America Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure North America Urological Cancer Drugs Consumption Share by End-Users in 2025

    • Table North America Urological Cancer Drugs Consumption by Major Countries from 2013 to 2025

    • Table North America Urological Cancer Drugs Consumption Share by Major Countries from 2013 to 2025

    • Figure North America Urological Cancer Drugs Consumption Share by Major Countries in 2013

    • Figure North America Urological Cancer Drugs Consumption Share by Major Countries in 2018

    • Figure North America Urological Cancer Drugs Consumption Share by Major Countries in 2025

    • Figure United States Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Canada Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Mexico Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Table Europe Urological Cancer Drugs Consumption by Types from 2013 to 2025

    • Table Europe Urological Cancer Drugs Consumption Share by Types from 2013 to 2025

    • Figure Europe Urological Cancer Drugs Consumption Share by Types in 2013

    • Figure Europe Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Europe Urological Cancer Drugs Consumption Share by Types in 2025

    • Table Europe Urological Cancer Drugs Consumption by End-Users from 2013 to 2025

    • Table Europe Urological Cancer Drugs Consumption Share by End-Users from 2013 to 2025

    • Figure Europe Urological Cancer Drugs Consumption Share by End-Users in 2013

    • Figure Europe Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Europe Urological Cancer Drugs Consumption Share by End-Users in 2025

    • Table Europe Urological Cancer Drugs Consumption by Major Countries from 2013 to 2025

    • Table Europe Urological Cancer Drugs Consumption Share by Major Countries from 2013 to 2025

    • Figure Europe Urological Cancer Drugs Consumption Share by Major Countries in 2013

    • Figure Europe Urological Cancer Drugs Consumption Share by Major Countries in 2018

    • Figure Europe Urological Cancer Drugs Consumption Share by Major Countries in 2025

    • Figure Germany Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure UK Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure France Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Italy Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Nordic Countries Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Belgium Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Poland Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Russia Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Turkey Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Table Asia Pacific Urological Cancer Drugs Consumption by Types from 2013 to 2025

    • Table Asia Pacific Urological Cancer Drugs Consumption Share by Types from 2013 to 2025

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by Types in 2013

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by Types in 2025

    • Table Asia Pacific Urological Cancer Drugs Consumption by End-Users from 2013 to 2025

    • Table Asia Pacific Urological Cancer Drugs Consumption Share by End-Users from 2013 to 2025

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by End-Users in 2013

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by End-Users in 2025

    • Table Asia Pacific Urological Cancer Drugs Consumption by Major Countries from 2013 to 2025

    • Table Asia Pacific Urological Cancer Drugs Consumption Share by Major Countries from 2013 to 2025

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by Major Countries in 2013

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by Major Countries in 2018

    • Figure Asia Pacific Urological Cancer Drugs Consumption Share by Major Countries in 2025

    • Figure China Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Japan Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Australia and New ZealandUrological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure India Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure ASEAN Countries Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure South Korea Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Table Latin America, Middle East & Africa Urological Cancer Drugs Consumption by Types from 2013 to 2025

    • Table Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Types from 2013 to 2025

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Types in 2013

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Types in 2025

    • Table Latin America, Middle East & Africa Urological Cancer Drugs Consumption by End-Users from 2013 to 2025

    • Table Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by End-Users from 2013 to 2025

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by End-Users in 2013

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by End-Users in 2025

    • Table Latin America, Middle East & Africa Urological Cancer Drugs Consumption by Major Countries from 2013 to 2025

    • Table Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Major Countries from 2013 to 2025

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Major Countries in 2013

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Major Countries in 2018

    • Figure Latin America, Middle East & Africa Urological Cancer Drugs Consumption Share by Major Countries in 2025

    • Figure GCC Countries Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Brazil Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Nigeria Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure South Africa Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Figure Argentina Urological Cancer Drugs Market Volume and Growth Rate from 2013 to 2025

    • Table Company Profile and Development Status of Abbott Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Abbott Laboratories

    • Figure Sales and Growth Rate Analysis of Abbott Laboratories

    • Figure Revenue and Market Share Analysis of Abbott Laboratories

    • Table Product and Service Introduction of Abbott Laboratories

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Roche Healthcare

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche Healthcare

    • Figure Sales and Growth Rate Analysis of Roche Healthcare

    • Figure Revenue and Market Share Analysis of Roche Healthcare

    • Table Product and Service Introduction of Roche Healthcare

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

    • Table Company Profile and Development Status of Ipsen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ipsen

    • Figure Sales and Growth Rate Analysis of Ipsen

    • Figure Revenue and Market Share Analysis of Ipsen

    • Table Product and Service Introduction of Ipsen

    • Table Company Profile and Development Status of Celgene Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celgene Corporation

    • Figure Sales and Growth Rate Analysis of Celgene Corporation

    • Figure Revenue and Market Share Analysis of Celgene Corporation

    • Table Product and Service Introduction of Celgene Corporation

    • Table Company Profile and Development Status of Astellas

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas

    • Figure Sales and Growth Rate Analysis of Astellas

    • Figure Revenue and Market Share Analysis of Astellas

    • Table Product and Service Introduction of Astellas

    • Table Company Profile and Development Status of Johnson & Johnson

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson

    • Figure Sales and Growth Rate Analysis of Johnson & Johnson

    • Figure Revenue and Market Share Analysis of Johnson & Johnson

    • Table Product and Service Introduction of Johnson & Johnson

    • Table Company Profile and Development Status of Dendreon Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dendreon Corporation

    • Figure Sales and Growth Rate Analysis of Dendreon Corporation

    • Figure Revenue and Market Share Analysis of Dendreon Corporation

    • Table Product and Service Introduction of Dendreon Corporation

    • Table Company Profile and Development Status of Tolmar Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Tolmar Inc

    • Figure Sales and Growth Rate Analysis of Tolmar Inc

    • Figure Revenue and Market Share Analysis of Tolmar Inc

    • Table Product and Service Introduction of Tolmar Inc

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Indevus Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Indevus Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Indevus Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Indevus Pharmaceuticals Inc

    • Table Product and Service Introduction of Indevus Pharmaceuticals Inc

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of Sanofi S.A.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi S.A.

    • Figure Sales and Growth Rate Analysis of Sanofi S.A.

    • Figure Revenue and Market Share Analysis of Sanofi S.A.

    • Table Product and Service Introduction of Sanofi S.A.

    • Table Company Profile and Development Status of Novartis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis

    • Figure Sales and Growth Rate Analysis of Novartis

    • Figure Revenue and Market Share Analysis of Novartis

    • Table Product and Service Introduction of Novartis

    • Table Company Profile and Development Status of Ferring Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ferring Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Ferring Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Ferring Pharmaceuticals

    • Table Product and Service Introduction of Ferring Pharmaceuticals


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US